LENZ · LENZ Therapeutics Inc
United States · RS rating 5 · As of 2026-10-14
| Price | 3.43 USD |
|---|---|
| 1-day change | +0.9% |
| RS rating (overall / 1M / 3M / 12M) | 5 / 12 / 12 / 3 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 15 / 14 / 9 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -96.6% |
| Sales growth Q/Q | -87.3% |
| Distance from 52-week high | +91.8% |
| Market cap (USD) | $286.9M |